This blog post reviews the recent history of acquisitions and investment in the area of decentralized molecular diagnostics. Kalorama Information’s The Market and Potential for Molecular Point of Care Diagnostics provides the current market, projected future sales and total available markets in 2020 for molecular POC diagnostics for flu, strep A, RSV, CT/NG, group B strep (GBS), HPV, HSV, vaginitis, HIV, TB, hepatitis, malaria and many other disease areas.
On May 16, Luminex Corporation announced a definitive agreement with Nanosphere, Inc. to acquire the latter for approximately $58 million. The acquisition will broaden Luminex’s addressable market in clinical molecular testing, adding platform capabilities and clients outside of the Luminex ARIES platform and xTAG panels. The Nanosphere Verigene and Verigene Flex platforms cater to the hospital market for automated molecular testing platforms, and could lead to opportunities in other decentralized markets for molecular testing (outside of centralized clinical labs or reference labs). Luminex’s acquisition of Nanosphere continues a string of company and technology acquisitions that have shaped the early molecular POC diagnostics industry.